The core uses a patent-pending, modified mRNA/miRNA-based method to reprogram somatic cells into induced pluripotent stem cells (iPSCs). This cutting-edge technology was developed by the co-directors of the core, Drs. Kogut and Bilousova (High-efficiency RNA-based reprogramming of human primary fibroblasts. Nature Communications. (2018). https://doi.org/10.1038/s41467-018-03190-3). It provides the following significant advantages over traditional cell reprogramming approaches such as lentiviral-, episomal-, and Sendai virus-based methods:
We provide up to 5 early passage iPSC clones per reprogrammed cell line (2 vials per clone)
Primary fibroblast lines provided by a customer, or isolated by the core from provided skin biopsies, are reprogrammed into iPSCs. Our protocol is approximately 18 days (iPSC colonies can be seen as early as day 13). If desired, a complete characterization profile can be provided post reprogramming.
|Fibroblast Isolation From Skin Biopsy||2 weeks|
|Fibroblast Reprogramming||2-3 weeks|
|iPSCs culturing and expansion||2 weeks|
|Mycoplasma test||1 week|
|Pluripotency Staining||1 week|
The core personnel is skilled in developing primary renal epithelial cell (REC) lines from human urine specimens and reprogramming REC lines into iPSCs. Please contact us for more information.
Note: a copy of approved IRB protocol(s) must be provided by customers before reprogramming patient-derived cells